Sage Therapeutics Announces Chief Executive Jeff Jonas to Undergo Scheduled Medical Procedure
Sage Therapeutics (NASDAQ: SAGE) announces that CEO Jeff Jonas, M.D. will undergo a scheduled surgical procedure today. The company expects him to make a full recovery and return to his role by December 2020. During his recovery, the Sage leadership team will oversee business operations, with support from the Board of Directors. Sage Therapeutics is focused on developing innovative therapies for brain disorders, aiming to improve brain health through its neurology, depression, and neuropsychiatry programs.
- Sage Therapeutics continues to have operational leadership during CEO's recovery.
- The Board of Directors remains engaged to guide company strategies.
- CEO Jeff Jonas's absence may temporarily impact company decision-making.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that Jeff Jonas, M.D., chief executive officer, will undergo a scheduled surgical procedure today. The Company anticipates he will make a full recovery and return to his role full-time in December 2020. While Dr. Jonas is recuperating, he will be available as needed, and during this time, the Sage leadership team will direct business operations. In addition, Sage’s experienced Board of Directors will continue to serve as a resource.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.
